ArrowMark Colorado Holdings LLC Has $27.29 Million Holdings in Agios Pharmaceuticals, Inc. $AGIO

ArrowMark Colorado Holdings LLC increased its stake in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 3.2% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 679,922 shares of the biopharmaceutical company’s stock after acquiring an additional 21,231 shares during the period. ArrowMark Colorado Holdings LLC owned 1.17% of Agios Pharmaceuticals worth $27,292,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in AGIO. NewEdge Advisors LLC bought a new stake in shares of Agios Pharmaceuticals during the 1st quarter worth $40,000. First Horizon Corp acquired a new stake in shares of Agios Pharmaceuticals in the third quarter valued at about $45,000. Quantbot Technologies LP bought a new position in shares of Agios Pharmaceuticals in the third quarter worth about $79,000. Acadian Asset Management LLC bought a new position in shares of Agios Pharmaceuticals in the first quarter worth about $133,000. Finally, PNC Financial Services Group Inc. lifted its position in shares of Agios Pharmaceuticals by 23.4% during the 2nd quarter. PNC Financial Services Group Inc. now owns 4,419 shares of the biopharmaceutical company’s stock worth $147,000 after purchasing an additional 837 shares during the last quarter.

Agios Pharmaceuticals Trading Up 0.9%

Shares of NASDAQ:AGIO opened at $27.85 on Friday. The firm has a market capitalization of $1.63 billion, a PE ratio of -3.92 and a beta of 0.89. Agios Pharmaceuticals, Inc. has a 1-year low of $22.24 and a 1-year high of $46.00. The business’s 50 day moving average is $28.14 and its 200-day moving average is $32.90.

Analyst Ratings Changes

A number of research firms have issued reports on AGIO. Bank of America raised their target price on Agios Pharmaceuticals from $32.00 to $34.00 and gave the company a “buy” rating in a report on Wednesday, December 24th. Royal Bank Of Canada cut Agios Pharmaceuticals from an “outperform” rating to a “sector perform” rating and reduced their price objective for the company from $57.00 to $28.00 in a research report on Wednesday, November 19th. JPMorgan Chase & Co. raised their price objective on shares of Agios Pharmaceuticals from $20.00 to $25.00 and gave the stock a “neutral” rating in a research note on Tuesday, January 6th. Citigroup boosted their target price on shares of Agios Pharmaceuticals from $38.00 to $46.00 and gave the stock a “buy” rating in a research report on Thursday, March 5th. Finally, HC Wainwright increased their price target on shares of Agios Pharmaceuticals from $62.00 to $65.00 and gave the company a “buy” rating in a report on Thursday, February 12th. Six investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $40.67.

Insider Buying and Selling

In other news, insider Tsveta Milanova sold 2,932 shares of the firm’s stock in a transaction dated Tuesday, December 30th. The shares were sold at an average price of $27.09, for a total transaction of $79,427.88. Following the completion of the transaction, the insider directly owned 29,190 shares of the company’s stock, valued at approximately $790,757.10. This trade represents a 9.13% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Brian Goff sold 18,703 shares of Agios Pharmaceuticals stock in a transaction dated Tuesday, December 30th. The shares were sold at an average price of $27.09, for a total transaction of $506,664.27. Following the sale, the chief executive officer owned 136,583 shares in the company, valued at approximately $3,700,033.47. This trade represents a 12.04% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 36,262 shares of company stock worth $984,237. Insiders own 4.30% of the company’s stock.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.